These days, the life sciences industry is all in on digital health. Or is it? On one hand, Abbot is integrating its CGM with Omada’s platform, Fitbit is linking up with two pharma players for early AFib detection, and Merck is testing machine learning to predict drug shortages. On the other, Novartis’ Sandoz is ending commercialization efforts with Pear Therapeutics—an indicator of just how tricky successful pharma-DTx alliances can be.
Ancestry Branches Out Into Genetic Health Screening
And it’s taking a different approach from competitor 23andMe WIRED | (Tweet)
Why Sony Is Launching A B2B Mobile Health Platform
One component: a smartwatch to measure health metrics MedCity News | (Tweet)
Walgreens Partners With Centene, RxAdvance On Cloud PBM
PBM rollup activity continues full speed ahead Forbes | (Tweet)